Zhaofu Wang

Zhaofu Wang

Auto-generated profile, based on publicly available information

Zhaofu Wang

Shanghai Blueray Biopharma Co., Ltd., Shanghai, China. 3

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
YDYong Du
Yong Du
YCYongfeng Chen
Yongfeng Chen
YWYuxia Wang
Yuxia Wang
JCJinju Chen
Jinju Chen
XLXiaorong Lu
Xiaorong Lu
GZGeorge Zhang
George Zhang
The EGFR C797S mutation is the most common on-target resistance mechanism to osimertinib in patients with advanced non–small cell lung cancer (NSCLC). Currently there are no effective treatment options for patients with NSCLC harboring EGFR C797S triple mutants (Del19/T790M/C797S and L858R/T790M/C797S). Herein, we report an orally bioavailable EGFR PROTAC, HJM-561, which selectively degrades the EGFR C797S-containing triple mutants. HJM-561 potently inhibits the proliferation of Del19/T790M/C797S and L858R/T790M/C797S Ba/F3 cells while sparing cells expressing wild-type EGFR. Oral administration of HJM-561 shows robust antitumor activity in EGFR Del19/T790M/C797S-driven Ba/F3 CDX and PDX models that were resistant to osimertinib treatment. Taken together, our results suggest that HJM-561 is a promising therapeutic option for overcoming EGFR triple mutation-mediated drug resistance in NSCLC. Watch the interview with George Zhang, PhD, recipient of the 2024 Molecular Cancer Therapeutics Award for Outstanding Journal Article: https://vimeo.com/992990122

22 April 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
YKYing Kong
Ying Kong
XZXinyue Zhao
Xinyue Zhao
ZWZhaofu Wang
Zhaofu Wang
SYSiqi Yuan
Siqi Yuan
SCSheng Chen
Sheng Chen
JWJuan Wang
Juan Wang
The aberrant activation of FGFR acts as a potent driver of multiple types of human cancers. Despite the development of several conventional small-molecular FGFR inhibitors, their clinical efficacy is largely compromised because of low selectivity and side effects. In this study, we report the selective FGFR1/2-targeting proteolysis-targeting chimera BR-cpd7 that displays significant isoform specificity to FGFR1/2 with half maximal degradation concentration values around 10 nmol/L while sparing FGFR3. The following mechanistic investigation reveals the reduced FGFR signaling, through which BR-cpd7 induces cell-cycle arrest and consequently blocks the proliferation of multiple FGFR1/2-dependent tumor cells. Importantly, BR-cpd7 has almost no antiproliferative activity against cancer cells without FGFR aberrations, furtherly supporting its selectivity. In vivo, BR-cpd7 exhibits robust antitumor effects in FGFR1-dependent lung cancer at well-tolerated dose schedules, accompanied by complete FGFR1 depletion. Overall, we identify BR-cpd7 as a promising candidate for developing a selective FGFR1/2-targeted agent, thereby offering a new therapeutic strategy for human cancers in which FGFR1/2 plays a critical role.

17 June 2026
Verified
Other
Open access
YKYing Kong
Ying Kong
XZXinyue Zhao
Xinyue Zhao
ZWZhaofu Wang
Zhaofu Wang
SYSiqi Yuan
Siqi Yuan
SCSheng Chen
Sheng Chen
JWJuan Wang
Juan Wang
BR-cpd7 suppresses tumor cell proliferation. A, KATO III cells were treated with BR-cpd7 or BGJ398 for 5 days. Cell proliferation was assessed with CellTiter-Glo (n=3 replicates). B, Immunoblot analysis of FGFR2 and PARP in KATO III cells after 40 h of incubation with BGJ398, BR-cpd7 or BR-cpd7 NC at 10, 100 or 1000 nM (n=3 replicates).

17 June 2026
Verified
Other
Open access
YKYing Kong
Ying Kong
XZXinyue Zhao
Xinyue Zhao
ZWZhaofu Wang
Zhaofu Wang
SYSiqi Yuan
Siqi Yuan
SCSheng Chen
Sheng Chen
JWJuan Wang
Juan Wang
Plasma protein binding data of BR-cpd7.

17 June 2026
Verified
Other
Open access
YKYing Kong
Ying Kong
XZXinyue Zhao
Xinyue Zhao
ZWZhaofu Wang
Zhaofu Wang
SYSiqi Yuan
Siqi Yuan
SCSheng Chen
Sheng Chen
JWJuan Wang
Juan Wang
BR-cpd7 selectively degrades FGFR1/2. A-C, Immunoblot analysis of FGFR1/2/3 proteins in DMS114 (A), KATO III (B), and RT112/84 (C) cells treated with BGJ398, BR-cpd7 or BR-cpd7 NC at 10, 100 or 1000 nM for 24 h (n=3 replicates). D and E, HEK293T cells transfected with HiBiT-FGFR1/2/3 were treated with BGJ398 (D) or BR-cpd7 NC (E) for 36 h. FGFR1/2/3 protein levels were quantified with Nano-Glo HiBiT (n=3 replicates). (F) Immunoblot analysis of FGFR1/2/3 levels in DMS114 under comparable exposure time (n=3 replicates).

17 June 2026
Verified
Other
Open access
YKYing Kong
Ying Kong
XZXinyue Zhao
Xinyue Zhao
ZWZhaofu Wang
Zhaofu Wang
SYSiqi Yuan
Siqi Yuan
SCSheng Chen
Sheng Chen
JWJuan Wang
Juan Wang
Anti-proliferative activity of BR-cpd7 and BGJ398 in multiple human cancer cell lines. Human cancer cells were subjected to different concentrations of BR-cpd7 or BGJ398, and IC50 at 4 or 5 days was calculated (n=3 replicates).